Brief: China's National Medical Products Administration (Nmpa) Approves PADCEV (Enfortumab Vedotin) For Treatment Of Locally Advanced Or Metastatic Urothelial Cancer
20/08/2024 24:34
Aug 19 (Reuters) - Astellas Pharma Inc 4503.T :
* CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)
APPROVES
PADCEV™ (ENFORTUMAB VEDOTIN) FOR TREATMENT OF LOCALLY ADVANCED
OR METASTATIC UROTHELIAL CANCER
Source text for Eikon: ID:nPn7GsLFYa
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn